Free Trial

Acrivon Therapeutics (ACRV) SEC Filings & 10K Form

Acrivon Therapeutics logo
$5.54 -0.31 (-5.30%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$5.66 +0.12 (+2.08%)
As of 02/21/2025 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Acrivon Therapeutics SEC Filings

DateFilerForm TypeView
02/19/2025
3:52 PM
Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
Masson Kristina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
3:53 PM
Acrivon Therapeutics (Issuer)
Devroe Eric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
3:54 PM
Acrivon Therapeutics (Issuer)
Gamelin Erick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
3:55 PM
Acrivon Therapeutics (Issuer)
Holm-Jorgensen Rasmus (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
3:59 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
5:04 PM
Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
Masson Kristina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
5:06 PM
Acrivon Therapeutics (Issuer)
Devroe Eric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
5:08 PM
Acrivon Therapeutics (Issuer)
Gamelin Erick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
5:10 PM
Acrivon Therapeutics (Issuer)
Holm-Jorgensen Rasmus (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
5:11 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2024
6:06 AM
Acrivon Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/13/2024
6:00 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/21/2024
3:22 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/11/2024
7:00 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/03/2024
5:49 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/16/2024
5:43 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/16/2024
3:52 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/16/2024
3:53 PM
Acrivon Therapeutics (Issuer)
Peterson Katharine (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2024
7:00 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/13/2024
6:36 AM
Acrivon Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/19/2024
3:20 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2024
7:29 PM
Acrivon Therapeutics (Subject)
Chione Ltd (Filed by)
Form SC 13G/A
07/10/2024
7:34 PM
Acrivon Therapeutics (Subject)
Chione Ltd (Filed by)
Form SC 13G/A
06/24/2024
4:36 PM
Acrivon Therapeutics (Issuer)
Kolchinsky Peter (Reporting)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
Shah Rajeev M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2024
4:26 PM
Acrivon Therapeutics (Issuer)
BAUM CHARLES M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2024
4:27 PM
Acrivon Therapeutics (Issuer)
DiRocco Derek (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2024
4:27 PM
Acrivon Therapeutics (Issuer)
Shacham Sharon (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2024
4:28 PM
Acrivon Therapeutics (Issuer)
TOMSICEK MICHAEL JOHN (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2024
5:56 PM
Acrivon Therapeutics (Issuer)
Devroe Eric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2024
5:58 PM
Acrivon Therapeutics (Issuer)
Gamelin Erick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2024
6:00 PM
Acrivon Therapeutics (Issuer)
Holm-Jorgensen Rasmus (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2024
6:02 PM
Acrivon Therapeutics (Issuer)
Masson Kristina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2024
6:03 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2024
6:05 PM
Acrivon Therapeutics (Issuer)
Peterson Katharine (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2024
5:52 PM
Acrivon Therapeutics (Issuer)
Peterson Katharine (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/16/2024
5:54 PM
Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2024
7:00 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2024
6:31 AM
Acrivon Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/29/2024
11:15 PM
Acrivon Therapeutics (Filer)
Form EFFECT
04/26/2024
7:30 AM
Acrivon Therapeutics (Filer)
Form DEF 14A
04/26/2024
7:30 AM
Acrivon Therapeutics (Filer)
Form DEF 14A
Market down? Do this now. (Ad)

During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.

Download your Free 2025 Gold Guide Now
04/26/2024
7:33 AM
Acrivon Therapeutics (Filer)
Acrivon Therapeutics (Filer)
Form DEFA14A
04/26/2024
7:36 AM
Acrivon Therapeutics (Filer)
Acrivon Therapeutics (Filer)
Form ARS
04/17/2024
3:39 PM
Acrivon Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
04/15/2024
7:53 AM
Acrivon Therapeutics (Issuer)
EDELMAN JOSEPH (Reporting)
PERCEPTIVE ADVISORS LLC (Reporting)
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2024
7:21 AM
Acrivon Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
Form SC 13G/A
04/11/2024
3:16 PM
Acrivon Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SC 13D/A
04/09/2024
6:05 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/29/2024
8:06 AM
Acrivon Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/28/2024
7:00 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/28/2024
6:36 AM
Acrivon Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/06/2024
3:32 PM
Acrivon Therapeutics (Issuer)
Palani Santhosh (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2024
7:15 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ACRV) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners